[go: up one dir, main page]

CN1329590A - 治疗产品及其应用 - Google Patents

治疗产品及其应用 Download PDF

Info

Publication number
CN1329590A
CN1329590A CN99813934A CN99813934A CN1329590A CN 1329590 A CN1329590 A CN 1329590A CN 99813934 A CN99813934 A CN 99813934A CN 99813934 A CN99813934 A CN 99813934A CN 1329590 A CN1329590 A CN 1329590A
Authority
CN
China
Prior art keywords
enantiomer
tramadol
product
treatment
racemic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99813934A
Other languages
English (en)
Chinese (zh)
Inventor
H·巴德斯雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Darwin Discovery Ltd
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9826537.4A external-priority patent/GB9826537D0/en
Priority claimed from GBGB9826535.8A external-priority patent/GB9826535D0/en
Priority claimed from GBGB9826536.6A external-priority patent/GB9826536D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of CN1329590A publication Critical patent/CN1329590A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
CN99813934A 1998-12-02 1999-12-02 治疗产品及其应用 Pending CN1329590A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9826537.4A GB9826537D0 (en) 1998-12-02 1998-12-02 Therapeutic product and its use
GB9826536.6 1998-12-02
GBGB9826535.8A GB9826535D0 (en) 1998-12-02 1998-12-02 Therapeutic product and its use
GB9826535.8 1998-12-02
GB9826537.4 1998-12-02
GBGB9826536.6A GB9826536D0 (en) 1998-12-02 1998-12-02 Therapeutic product and its use

Publications (1)

Publication Number Publication Date
CN1329590A true CN1329590A (zh) 2002-01-02

Family

ID=27269570

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99813934A Pending CN1329590A (zh) 1998-12-02 1999-12-02 治疗产品及其应用

Country Status (12)

Country Link
EP (1) EP1135361A1 (fr)
JP (1) JP2002531431A (fr)
KR (1) KR20010080364A (fr)
CN (1) CN1329590A (fr)
AU (1) AU1400100A (fr)
BR (1) BR9915873A (fr)
CA (1) CA2350635A1 (fr)
HU (1) HUP0104420A2 (fr)
IL (1) IL142778A0 (fr)
NO (1) NO20012738D0 (fr)
PL (1) PL347542A1 (fr)
WO (1) WO2000032558A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1313460A2 (fr) * 1999-11-09 2003-05-28 Darwin Discovery Limited Utilisation therapeutique et formulation de (-)-tramadol
IL155102A0 (en) * 2000-10-03 2003-10-31 Penwest Pharmaceuticals Co Delivery system for multi-pharmaceutical active materials at various release rates
DE10108122A1 (de) 2001-02-21 2002-10-02 Gruenenthal Gmbh Arzneimittel auf Basis von Tramadol
US6780891B2 (en) 2001-11-30 2004-08-24 Sepracor Inc. Tramadol analogs and uses thereof
BRPI0615860B8 (pt) 2005-09-09 2021-05-25 Labopharm Barbados Ltd composição farmacêutica de liberação prolongada monolítica sólida
US20080261991A1 (en) 2007-02-12 2008-10-23 Dmi Biosciences, Inc. Reducing Side Effects of Tramadol
AU2008259841B2 (en) * 2007-05-31 2015-02-05 Sunovion Pharmaceuticals Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
JOP20190251A1 (ar) * 2017-05-31 2019-10-21 Metys Pharmaceuticals AG تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية
CN118955352A (zh) 2017-12-05 2024-11-15 赛诺维信制药公司 晶体形式及其制备方法
CN112118838A (zh) 2017-12-05 2020-12-22 赛诺维信制药公司 非外消旋混合物及其用途
WO2020115096A1 (fr) * 2018-12-04 2020-06-11 Metys Pharmaceuticals AG Compositions synergiques comprenant du r-2-(sulfonyle substitué)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones et du s-2-(sulfonyle substitué)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones selon un rapport non racémique
WO2020247627A1 (fr) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Formulations à libération modifiée et utilisations associées

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
EP0969818B1 (fr) * 1997-03-11 2004-09-08 Arakis Ltd. Formes galeniques comprenant des parties separees d'enantiomeres r et s
DE19807535A1 (de) * 1998-02-21 1999-08-26 Asta Medica Ag Pharmazeutische Kombinationen mit Tramadol

Also Published As

Publication number Publication date
KR20010080364A (ko) 2001-08-22
JP2002531431A (ja) 2002-09-24
AU1400100A (en) 2000-06-19
IL142778A0 (en) 2002-03-10
HUP0104420A2 (en) 2002-08-28
NO20012738L (no) 2001-06-01
BR9915873A (pt) 2001-08-21
PL347542A1 (en) 2002-04-08
NO20012738D0 (no) 2001-06-01
WO2000032558A1 (fr) 2000-06-08
EP1135361A1 (fr) 2001-09-26
CA2350635A1 (fr) 2000-06-08

Similar Documents

Publication Publication Date Title
O’Brien Drug addiction and drug abuse
RU2140266C1 (ru) Фармацевтическая композиция с регулируемым выделением на основе одной или нескольких фармацевтически приемлемых солей гамма-гидроксимасляной кислоты и способ ее получения
Grond et al. Clinical pharmacology of tramadol
US9456985B2 (en) Sustained-released product comprising a combination of a non-opioid amine and a non-steroidal, anti-inflammatory drug
CN1329590A (zh) 治疗产品及其应用
JP2007522249A (ja) 精神医学的状態の処置のための、ｎｍｄａレセプターアンタゴニストと、抗うつ薬であるｍａｏインヒビターまたはｇａｄｐｈインヒビターとの併用
US20240074993A1 (en) Methods of treating or preventing an attention disorder, cognitive disorder, and/or dementia associated with a neurodegenerative disorder
Zacny et al. Psychotropic drugs used in anesthesia practice: abuse liability and epidemiology of abuse
EP1313460A2 (fr) Utilisation therapeutique et formulation de (-)-tramadol
Slattery et al. Levalbuterol hydrochloride
AU758103B2 (en) Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain
MXPA01005242A (en) Therapeutic product and its use
WO2005067909A1 (fr) Therapie combinee comprenant l'utilisation de mecamylamine dans le traitement des troubles de l'humeur
JP4318899B2 (ja) 抗感冒剤
CN1946292B (zh) 减少共同滥用可能性的方法
JP2008519016A (ja) 新規な医薬品組成物および様々な形の薬物嗜癖を制御するためのそれらの使用
WO2022065362A1 (fr) Formulation pour administration orale
NZ718978B2 (en) Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder
MXPA06004782A (es) Formulacion oral antidepresiva que comprende acido acetilsalicilico para acelerar la presentacion de la accion
AU2001226574A1 (en) Methods for the treatment of substance abuse

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication